Last34.14 -0.71 (-2.04%)
17.26 - 44.8
52 Week Range
Technical Indicators (Daily)
We think all investors should try to buy and hold high quality multi-year winners. And highest quality companies can......
Here's Why We Think Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) CEO Compensation Looks Fair for the time being
Performance at Intra-Cellular Therapies, Inc. ( NASDAQ:ITCI ) has been reasonably good and CEO Sharon Mates has done a......
CAPLYTA® (lumateperone) Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical Psychopharmacology
Pooled analysis of 3 randomized, double-blind, pacebo-cotrolled trials supports the safety and the distinct and favorable tolerability profile of lumateperone 42 mg Mean change from baseline in metabo...
NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervo...
ITCI earnings call for the period ending March 31, 2021....
Disclaimer: The data contained in Super Surge website is not necessarily real-time nor accurate and may differ from the actual market data. Prices, volumes, ratios, charts and indicators are indicative and not appropriate for trading purposes. Super Surge doesn't bear any responsibility for any trading losses you might incur as a result of using this data.